NuVasive, Inc. (NUVA) CEO Purchases $123,040.00 in Stock

NuVasive, Inc. (NASDAQ:NUVA) CEO Gregory T. Lucier acquired 2,000 shares of the firm’s stock in a transaction on Tuesday, August 29th. The stock was bought at an average price of $61.52 per share, for a total transaction of $123,040.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of NuVasive, Inc. (NUVA) traded down 0.78% during midday trading on Wednesday, reaching $59.72. 278,024 shares of the company’s stock were exchanged. NuVasive, Inc. has a 12 month low of $56.70 and a 12 month high of $81.68. The firm has a 50 day moving average price of $65.55 and a 200 day moving average price of $72.74. The company has a market cap of $3.03 billion, a P/E ratio of 94.05 and a beta of 1.08.

NuVasive (NASDAQ:NUVA) last released its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The company had revenue of $260.60 million for the quarter, compared to analysts’ expectations of $261.95 million. During the same period last year, the firm posted $0.40 earnings per share. NuVasive’s revenue was up 10.3% compared to the same quarter last year. Equities research analysts forecast that NuVasive, Inc. will post $2.00 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://stocknewstimes.com/2017/09/13/gregory-t-lucier-buys-2000-shares-of-nuvasive-inc-nuva-stock.html.

Hedge funds have recently bought and sold shares of the business. Westside Investment Management Inc. bought a new position in NuVasive in the first quarter valued at about $109,000. FNY Partners Fund LP bought a new position in NuVasive in the first quarter valued at about $112,000. Neuburgh Advisers LLC lifted its holdings in NuVasive by 18.3% in the first quarter. Neuburgh Advisers LLC now owns 1,552 shares of the medical device company’s stock valued at $116,000 after acquiring an additional 240 shares during the period. SpiderRock Advisors LLC bought a new position in NuVasive in the first quarter valued at about $124,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in NuVasive by 9.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,901 shares of the medical device company’s stock valued at $146,000 after acquiring an additional 158 shares during the period.

Several equities analysts have commented on NUVA shares. Cowen and Company reiterated an “outperform” rating and issued a $90.00 price objective (up from $85.00) on shares of NuVasive in a report on Wednesday, June 28th. Robert W. Baird downgraded shares of NuVasive from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $79.00 to $72.00 in a research note on Friday, July 28th. Gabelli restated a “buy” rating on shares of NuVasive in a research note on Monday, July 31st. Royal Bank Of Canada restated a “buy” rating and issued a $85.00 price target on shares of NuVasive in a research note on Thursday, July 20th. Finally, Zacks Investment Research downgraded shares of NuVasive from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $80.42.

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Insider Buying and Selling by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply